White paper

Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

This white paper explores the unique challenges of ODs for RDs and the different approaches needed to address specific questions for their successful commercialization that vary fr ...

White paper

Growing Attention Being Paid To Pharma Company Rebates And Discounts

Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...

White paper

Perspectives On Pharma Company Use Of Open Payments Data

This paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies and cha ...

White paper

How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?

The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, a ...

White paper

Is The CVS-Aetna Merger A Pharma Industry Transformative Event?

US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Expres ...

White paper

Deploying Successful Global Incentive Compensation Capabilities

There exists no single formula to solve the incentive compensation management puzzle, especially at a global scale across multiple geographies. The answer lies in a global IC plan ...

Article

The Causes and Solutions of Chronic Drug Shortages in the United States

While recent empirical research has exposed an array of causes for drug shortages, the application of better analytics has now also been cited as needed to account for these effect ...

White paper

Aligning Sales to the Field Force – Increasing Complexities with Change in the Pharma Landscape

With this Whitepaper, unravel means of actual and correct sales crediting and therefore reduce pitfalls in incentive payouts through assigning correct addresses, managing shared ta ...

White paper

The Value of Machine Learning and Data Mining in Pharmaceutical Commercial Analytics

Increasing complexities of the pharma environment also mean that machine learning can provide earlier anticipation of and faster responses to new threats and opportunities. ...

White paper

Evolution of Pharmaceutical Call Planning

This white paper will explore the factors used to develop account based call plans and how pharmaceutical companies’ must adapt to ensure their representatives are prepared and q ...

White paper

Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary

No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (D ...

White paper

Regional Sales And Marketing Optimization Modeling: A Call For Technical Changes

The concept of “all marketing is local” in the pharma environment is more valid today than ever before. We see tremendous variations in salient factors that would affect commer ...

White paper

Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

This white paper explores the unique challenges of ODs for RDs and the different approaches needed to address specific questions for their successful commercialization that vary fr ...

White paper

Growing Attention Being Paid To Pharma Company Rebates And Discounts

Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...

White paper

Perspectives On Pharma Company Use Of Open Payments Data

This paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies and cha ...

White paper

How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?

The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, a ...

White paper

Is The CVS-Aetna Merger A Pharma Industry Transformative Event?

US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Expres ...

White paper

Deploying Successful Global Incentive Compensation Capabilities

There exists no single formula to solve the incentive compensation management puzzle, especially at a global scale across multiple geographies. The answer lies in a global IC plan ...

Article

The Causes and Solutions of Chronic Drug Shortages in the United States

While recent empirical research has exposed an array of causes for drug shortages, the application of better analytics has now also been cited as needed to account for these effect ...

White paper

Aligning Sales to the Field Force – Increasing Complexities with Change in the Pharma Landscape

With this Whitepaper, unravel means of actual and correct sales crediting and therefore reduce pitfalls in incentive payouts through assigning correct addresses, managing shared ta ...

White paper

The Value of Machine Learning and Data Mining in Pharmaceutical Commercial Analytics

Increasing complexities of the pharma environment also mean that machine learning can provide earlier anticipation of and faster responses to new threats and opportunities. ...

White paper

Evolution of Pharmaceutical Call Planning

This white paper will explore the factors used to develop account based call plans and how pharmaceutical companies’ must adapt to ensure their representatives are prepared and q ...

White paper

Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary

No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (D ...

White paper

Regional Sales And Marketing Optimization Modeling: A Call For Technical Changes

The concept of “all marketing is local” in the pharma environment is more valid today than ever before. We see tremendous variations in salient factors that would affect commer ...

White paper

Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

This white paper explores the unique challenges of ODs for RDs and the different approaches needed to address specific questions for their successful commercialization that vary fr ...

White paper

Growing Attention Being Paid To Pharma Company Rebates And Discounts

Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...

White paper

Perspectives On Pharma Company Use Of Open Payments Data

This paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies and cha ...

White paper

How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?

The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, a ...

White paper

Is The CVS-Aetna Merger A Pharma Industry Transformative Event?

US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Expres ...

White paper

Deploying Successful Global Incentive Compensation Capabilities

There exists no single formula to solve the incentive compensation management puzzle, especially at a global scale across multiple geographies. The answer lies in a global IC plan ...

Article

The Causes and Solutions of Chronic Drug Shortages in the United States

While recent empirical research has exposed an array of causes for drug shortages, the application of better analytics has now also been cited as needed to account for these effect ...

White paper

Aligning Sales to the Field Force – Increasing Complexities with Change in the Pharma Landscape

With this Whitepaper, unravel means of actual and correct sales crediting and therefore reduce pitfalls in incentive payouts through assigning correct addresses, managing shared ta ...

White paper

The Value of Machine Learning and Data Mining in Pharmaceutical Commercial Analytics

Increasing complexities of the pharma environment also mean that machine learning can provide earlier anticipation of and faster responses to new threats and opportunities. ...

White paper

Evolution of Pharmaceutical Call Planning

This white paper will explore the factors used to develop account based call plans and how pharmaceutical companies’ must adapt to ensure their representatives are prepared and q ...

White paper

Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary

No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (D ...

White paper

Regional Sales And Marketing Optimization Modeling: A Call For Technical Changes

The concept of “all marketing is local” in the pharma environment is more valid today than ever before. We see tremendous variations in salient factors that would affect commer ...

White paper

Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

This white paper explores the unique challenges of ODs for RDs and the different approaches needed to address specific questions for their successful commercialization that vary fr ...

White paper

Growing Attention Being Paid To Pharma Company Rebates And Discounts

Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...

White paper

Perspectives On Pharma Company Use Of Open Payments Data

This paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies and cha ...

White paper

How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?

The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, a ...

White paper

Is The CVS-Aetna Merger A Pharma Industry Transformative Event?

US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Expres ...

White paper

Deploying Successful Global Incentive Compensation Capabilities

There exists no single formula to solve the incentive compensation management puzzle, especially at a global scale across multiple geographies. The answer lies in a global IC plan ...

Article

The Causes and Solutions of Chronic Drug Shortages in the United States

While recent empirical research has exposed an array of causes for drug shortages, the application of better analytics has now also been cited as needed to account for these effect ...

White paper

Aligning Sales to the Field Force – Increasing Complexities with Change in the Pharma Landscape

With this Whitepaper, unravel means of actual and correct sales crediting and therefore reduce pitfalls in incentive payouts through assigning correct addresses, managing shared ta ...

White paper

The Value of Machine Learning and Data Mining in Pharmaceutical Commercial Analytics

Increasing complexities of the pharma environment also mean that machine learning can provide earlier anticipation of and faster responses to new threats and opportunities. ...

White paper

Evolution of Pharmaceutical Call Planning

This white paper will explore the factors used to develop account based call plans and how pharmaceutical companies’ must adapt to ensure their representatives are prepared and q ...

White paper

Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary

No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (D ...

White paper

Regional Sales And Marketing Optimization Modeling: A Call For Technical Changes

The concept of “all marketing is local” in the pharma environment is more valid today than ever before. We see tremendous variations in salient factors that would affect commer ...

Let us help your business today.
Contact us now to start your journey.